HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $181 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on BioNTech (NASDAQ:BNTX) and maintained a $181 price target.
June 09, 2023 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on BioNTech and maintained a $181 price target.
The reiteration of the Buy rating and maintenance of the $181 price target by HC Wainwright & Co. analyst Robert Burns indicates a positive outlook for BioNTech's stock. This news is directly related to BNTX and is important for investors as it reflects the analyst's confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100